Women with menopausal symptoms may benefit from hormone replacement treatment, often known as menopausal hormone therapy. As women approach menopause, their reduced hormone levels are replaced with hormone replacement therapy. Hormone replacement therapy comes in various forms, such as thyroid hormone replacement therapy, hormone replacement therapy, and growth hormone replacement therapy.
The market for hormone replacement therapy in 2021 was USD 24.97 billion and will reach USD 49.25 billion by 2030, growing at a 7.83% CAGR during 2021-2030.
Major participants would raise their product approvals and extend their R&D activities to develop novel medicines to address hormonal imbalances. Two major factors responsible for the growth of the global market for hormone replacement therapy are the rising prevalence of menopausal diseases and women’s increased awareness of the issues related to post-menopause.
Market Dynamics: Driver and Restraints
The main forces behind the growth of hormone replacement therapy are the rising need for regeneration drugs such as menopause hormone replacement and anti-aging treatments. Due to these medications’ generally safe profiles, effectiveness, and affordability, rising demand in additional therapeutic areas, like growth hormone therapy and thyroid hormone therapy, will have a beneficial effect on market growth.
Moreover, throughout the projected period, the market for hormone replacement therapy will develop due to innovative formulations, including transdermal medications, gels, and creams that provide advantages like the convenience of drug administration and location-specific impact. The market for hormone replacement treatment will rise due to benefits such as a decreased risk of osteoporosis, cardiovascular disease, and vasomotor symptoms.
Side effects of hormone replacement therapy include sadness, indigestion, headaches, and fluid retention. These are likely to reduce the therapeutic field’s appeal. Furthermore, the UK-based NICE organization warns that taking estrogen and progesterone together while undergoing hormone replacement treatment may increase the chance of developing breast cancer. Long-term use of HRT medications may also raise the risk of blood clots. Less than two blood clots are predicted to form for every 1,000 women using HRT pills for 7.5 years, according to studies.
Therapy Type Insights
On the basis of therapy type, the market is segmented into testosterone hormone replacement therapy, Estrogen Hormone Replacement Therapy, Progestogen Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy, and Human Growth Hormone Replacement Therapy.
The estrogen and progesterone replacement therapy segment ruled the entire market, with the largest share of 53.15% in 2021. One of the most popular and often-used therapies among menopausal women worldwide is estrogen hormone replacement. The market is expanding due to women using more estrogen hormone replacement therapy.
Route of administration Insights
On the basis of the route of administration, the market is segmented into parenteral, oral, transdermal, and others.
In 2021, the oral segment ruled the entire market because it is so easily administered and has a high prescription rate. Tablets and pills are typically included in HRT medicines.
During the projected time, the parenteral segment will have profitable expansion. The category is expected to grow due to improvements in parenteral drug delivery techniques, such as pen-based medication delivery, which are expected to increase patient compliance and simplify administration.
Disease Type Insights
On the basis of disease types, the market is segmented into menopause, male hypogonadism, hypothyroidism, growth hormone insufficiency, and hypoparathyroidism. In 2021, the menopausal category ruled the market. It is due to the rise in the number of women experiencing menopause.
Due to an increase in new treatments and product introductions, the hypoparathyroidism segment will grow significantly throughout the projected period.
North America held the maximum market position, with a share of 37.54% in 2021. The biggest market share in the area is a result of a number of reasons, including significant product launches, manufacturer collaboration agreements, and benevolent reimbursement policies. For instance, Novo Nordisk A/Sogroya S’s (somapacitan-beco), a medication for HGH replacement therapy, received FDA approval in August 2020.
Asia Pacific will grow at a rapid CAGR during the forecast period. The prevalence of vasomotor symptoms linked with menopause has been observed to range from 43% to 83% among women in East Asian countries, according to the Journal of the North American Menopause Society (May 2022). Thus, the region’s demand for hormone replacement therapy will increase as more women enter menopause.
Key Players in the hormone replacement therapy market
- Eli Lily And Company
- Hoffmann-La Roche Ltd. (Genentech, Inc.)
- Merck Kgaa
- Mylan N.V. (Viatris Inc.)
- Abbott Laboratories
- Bayer Ag.
- Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.)
- Novo Nordisk A/S
- Novartis International Ag
- Pfizer Inc.
The market for hormone replacement therapy in 2021 was USD 24.97 billion and will reach USD 49.25 billion by 2030, growing at a 7.83% CAGR during 2021-2030. Major factors fostering the growth of the hormone replacement therapy market are the rise in menopausal sickness prevalence and growing awareness of post-menopausal issues among women.